Akero Therapeutics, Inc
Clinical trials sponsored by Akero Therapeutics, Inc, explained in plain language.
-
Major trial aims to halt progression of scarred livers
Disease control Recruiting nowThis large, late-stage study is testing whether a drug called efruxifermin can slow down or reverse liver damage in people who already have significant scarring (cirrhosis) from fatty liver disease (NASH/MASH). About 1,150 participants will receive either the drug or a placebo to…
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Major trial tests new drug to halt scarring in fatty liver disease
Disease control Recruiting nowThis large, late-stage study is testing whether the drug efruxifermin can help people with a serious form of fatty liver disease called NASH or MASH, which causes liver inflammation and scarring. It will enroll 1,650 adults with moderate to advanced liver scarring but not full ci…
Phase: PHASE3 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC